A Phase 1 interventional study of Amlodipine and Amlodipine in Healthy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is being conducted to determine if 5 mg amlodipine 3rd Orally-Disintegrating (OD) tablet (new formulation) and 5 mg amlodipine 2nd OD tablet (commercial formulation) are bioequivalent.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
24 subjects (12 subjects per sequence) will receive treatment A) one 5 mg amlodipine 3rd OD tablet (test) with water and treatment B) one 5 mg amlodipine 2nd OD tablet (reference) with water.
Drug: Amlodipine
24 subjects (12 subjects per sequence) will receive treatment C) one 5 mg amlodipine 3rd OD tablet (test) without water, and treatment D) one 5 mg amlodipine 2nd OD tablet (reference) without water
Drug: Amlodipine
3rd OD 5 mg tablet single oral dose administered with water
2nd OD 5 mg tablet single oral dose administered with water
3rd OD 5 mg tablet single oral dose administered without water
2nd OD 5 mg tablet single oral dose administered without water
Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt)
Area under the concentration-time curve from zero time until the last sampling time
Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Maximum Observed Plasma Concentration (Cmax)
Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast), Area Under the Plasma Concentration-Time Curve to Infinity (AUCinf)
AUC last = Area under the concentration versus time curve from zero time until the last measurable concentration is calculated using the trapezoidal rule. AUCinf = AUClast + (Ct / kel), where Ct is the estimated concentration at the last measurable concentration.
Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Apparent Terminal Elimination Phase Rate Constant (Kel)
Estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile.
Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Apparent Terminal Elimination Half-Life (T-half)
Terminal phase half-life calculated as ln(2) / kel
Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Mean Residence Time (MRT)
MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from zero time to infinity calculated as AUMCinf = AUMCt + ((t x Ct) / kel) + (Ct / kel\^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method.
Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Participants were screened at one center in Japan.
| Milestone | 3rd OD Tablet With Water, Then 2nd OD Tablet With Water | 2nd OD Tablet With Water, Then 3rd OD Tablet With Water | 3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water | 2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water |
|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 |
| Completed | 12 | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 3rd OD Tablet With Water, Then 2nd OD Tablet With Water | 2nd OD Tablet With Water, Then 3rd OD Tablet With Water | 3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water | 2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water |
|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 |
| Completed | 12 | 11 | 12 | 12 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Milestone | 3rd OD Tablet With Water, Then 2nd OD Tablet With Water | 2nd OD Tablet With Water, Then 3rd OD Tablet With Water | 3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water | 2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water |
|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 |
| Completed | 12 | 11 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
Area under the concentration-time curve from zero time until the last sampling time
| ng*h/mL | Cohort I: 3rd OD Tablet (Test) With Water | Cohort I: 2nd OD Tablet (Reference) With Water | Cohort II: 3rd OD Tablet (Test) Without Water | Cohort II: 2nd OD Tablet (Reference) Without Water |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt) | 126.36 ± 33.16 | 129.48 ± 39.93 | 122.33 ± 32.59 | 119.75 ± 28.23 |
| ng/mL | Cohort I: 3rd OD Tablet (Test) With Water | Cohort I: 2nd OD Tablet (Reference) With Water | Cohort II: 3rd OD Tablet (Test) Without Water | Cohort II: 2nd OD Tablet (Reference) Without Water |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 2.70 ± 0.513 | 2.74 ± 0.650 | 2.48 ± 0.470 | 2.45 ± 0.409 |
AUC last = Area under the concentration versus time curve from zero time until the last measurable concentration is calculated using the trapezoidal rule. AUCinf = AUClast + (Ct / kel), where Ct is the estimated concentration at the last measurable concentration.
| ng*h/mL | Cohort I: 3rd OD Tablet (Test) With Water | Cohort I: 2nd OD Tablet (Reference) With Water | Cohort II: 3rd OD Tablet (Test) Without Water | Cohort II: 2nd OD Tablet (Reference) Without Water |
|---|---|---|---|---|
| AUClast | 124.14 ± 33.96 | 127.36 ± 40.91 | 121.05 ± 33.76 | 118.27 ± 29.43 |
| AUCinf | 142.87 ± 43.20 | 145.22 ± 49.19 | 140.41 ± 42.18 | 138.14 ± 34.10 |
Estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile.
| L/h | Cohort I: 3rd OD Tablet (Test) With Water | Cohort I: 2nd OD Tablet (Reference) With Water | Cohort II: 3rd OD Tablet (Test) Without Water | Cohort II: 2nd OD Tablet (Reference) Without Water |
|---|---|---|---|---|
| Apparent Terminal Elimination Phase Rate Constant (Kel) | 0.0174 ± 0.0031 | 0.0179 ± 0.0035 | 0.0162 ± 0.0041 | 0.0156 ± 0.0031 |
Terminal phase half-life calculated as ln(2) / kel
| hour | Cohort I: 3rd OD Tablet (Test) With Water | Cohort I: 2nd OD Tablet (Reference) With Water | Cohort II: 3rd OD Tablet (Test) Without Water | Cohort II: 2nd OD Tablet (Reference) Without Water |
|---|---|---|---|---|
| Apparent Terminal Elimination Half-Life (T-half) | 41.45 ± 9.76 | 40.27 ± 8.48 | 45.04 ± 10.16 | 46.20 ± 8.85 |
MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from zero time to infinity calculated as AUMCinf = AUMCt + ((t x Ct) / kel) + (Ct / kel\^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method.
| hour | Cohort I: 3rd OD Tablet (Test) With Water | Cohort I: 2nd OD Tablet (Reference) With Water | Cohort II: 3rd OD Tablet (Test) Without Water | Cohort II: 2nd OD Tablet (Reference) Without Water |
|---|---|---|---|---|
| Mean Residence Time (MRT) | 61.29 ± 13.55 | 59.77 ± 11.99 | 66.18 ± 14.10 | 67.33 ± 11.90 |
| hour | Cohort I: 3rd OD Tablet (Test) With Water | Cohort I: 2nd OD Tablet (Reference) With Water | Cohort II: 3rd OD Tablet (Test) Without Water | Cohort II: 2nd OD Tablet (Reference) Without Water |
|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 8 (4 to 12) | 8 (4 to 12) | 8 (6 to 12) | 8 (6 to 12) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort I: 3rd OD Tablet (Test) With Water | — | 0/23 (0%) | 7/23 (30.4%) |
| Cohort I: 2nd OD Tablet (Reference) With Water | — | 0/24 (0%) | 6/24 (25%) |
| Cohort II: 3rd OD Tablet (Test) Without Water | — | 0/24 (0%) | 2/24 (8.3%) |
| Cohort II: 2nd OD Tablet (Reference) Without Water | — | 0/24 (0%) | 3/24 (12.5%) |
| Event | Cohort I: 3rd OD Tablet (Test) With Water | Cohort I: 2nd OD Tablet (Reference) With Water | Cohort II: 3rd OD Tablet (Test) Without Water | Cohort II: 2nd OD Tablet (Reference) Without Water |
|---|---|---|---|---|
| HeadacheNervous system disorders | 2/23 | 1/24 | 0/24 | 1/24 |
| Abdominal discomfortGastrointestinal disorders | 1/23 | 0/24 | 0/24 | 0/24 |
| ToothacheGastrointestinal disorders | 1/23 | 1/24 | 0/24 | 0/24 |
| PharingitisInfections and infestations | 1/23 | 0/24 | 0/24 | 0/24 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/23 | 0/24 | 0/24 | 0/24 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 1/23 | 1/24 | 0/24 | 0/24 |
| Oropharyngeal disconfortRespiratory, thoracic and mediastinal disorders | 1/23 | 1/24 | 0/24 | 0/24 |
| DiarrhoeaGastrointestinal disorders | 0/23 | 0/24 | 1/24 | 0/24 |
| StomatitisGastrointestinal disorders | 0/23 | 0/24 | 0/24 | 1/24 |
| Blood bilirubin increasedInvestigations | 0/23 | 1/24 | 0/24 | 0/24 |
| Age, Continuous(years) | 3rd OD Tablet With Water, Then 2nd OD Tablet With Water | 2nd OD Tablet With Water, Then 3rd OD Tablet With Water | 3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water | 2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water | Total |
|---|---|---|---|---|---|
| Mean | 33.8 ± 10.7 | 32.4 ± 11.1 | 37.3 ± 9.0 | 37.8 ± 12.1 | 33.1 ± 10.7 |
| Sex: Female, Male(Participants) | 3rd OD Tablet With Water, Then 2nd OD Tablet With Water | 2nd OD Tablet With Water, Then 3rd OD Tablet With Water | 3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water | 2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 12 | 12 | 12 | 12 | 48 |
The record gives a start of Nov 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →